🦠 microbiology

Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains

This study characterizes the multifactorial mechanisms of cefiderocol resistance in French *Pseudomonas aeruginosa* clinical strains, identifying acquired $\beta$ -lactamases (particularly NDM-1 and ESBLs) and impaired siderophore uptake (notably via PirR inactivation) as the primary drivers of high-level resistance, underscoring the critical need for routine surveillance and caution when treating NDM-producing isolates.

Original authors: GAUTHIER, E., PISANI, M., BOUR, M., GROSJEAN, M., Plesiat, P., SAFARI, S., Hartkoorn, R. C., SOURO, L., Pretot, E., Jeannot, K.

Published 2026-04-16

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: GAUTHIER, E., PISANI, M., BOUR, M., GROSJEAN, M., Plesiat, P., SAFARI, S., Hartkoorn, R. C., SOURO, L., Pretot, E., Jeannot, K.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

This study elucidates why a drug known as the "strongest antibiotic," Cefiderocol, becomes ineffective against a specific bacterium (Pseudomonas aeruginosa), by conducting a detailed investigation of 103 bacterial strains collected from hospitals in France.

Let us imagine this as a story where "bacteria devise various tricks to evade the police (antibiotics) armed with the strongest weapons."

🏰 The Setting of the Story: Pseudomonas aeruginosa and the Strongest Police

Pseudomonas aeruginosa: A very tough bacterium that frequently causes problems in hospitals.
Cefiderocol: Previously expected to be the "strongest special forces unit," it was anticipated to infiltrate the bacterial fortress (cell) by disguising itself as a "truck transporting iron (ions)" and destroy it from within.

However, this study revealed that even the "strongest special forces unit" can be rendered powerless if the enemy employs several tricks.

🔑 Three "Tricks" Used by Bacteria

This study identified three primary methods bacteria use to render Cefiderocol ineffective.

1. Breaking the "Castle Gate" (Blocking the Iron Truck)

Cefiderocol enters the castle by riding on a "iron truck (transporter)" that bacteria use to transport "iron."

Trick: Bacteria broke the driver's switch (a protein called PirR) or eliminated the truck itself (such as PiuA).
Result: The special forces unit (Cefiderocol) cannot board the "iron truck" and becomes stranded outside the castle.
Discovery: Remarkably, many bacteria were found to use the same trick of breaking the driver's switch called "PirR." This is evidence that bacteria are exploiting the same vulnerability.

2. Reinforcing the "Shield" (Degrading the Drug with Enzymes)

Even if it enters the castle, bacteria possess a "shield (enzyme)" that neutralizes attacks.

Trick: Bacteria acquired powerful "shields (β-lactamase enzymes)" such as "NDM-1" and "VEB-1" from the outside.
Result: Even when Cefiderocol attempts to attack, it is repelled and degraded by this shield. Bacteria possessing the "NDM-1" shield are particularly dangerous, with many cases showing complete ineffectiveness of Cefiderocol.
Unexpected Discovery: A new shield called "PAC-1," previously thought to be non-degradable by Cefiderocol, was found to actually possess strong degradative power.

3. Thickening the "Castle Walls" (Altering the Target)

Inside the bacteria, there is a "target (a protein called PBP-3)" that Cefiderocol attacks.

Trick: Bacteria slightly altered the shape of this "target" (through mutations such as E219K).
Result: Even when the special forces unit attacks, the altered shape of the target means the strike misses its mark, and the attack fails.

🧩 The Greatest Lesson: "Combination Moves" Are Strongest

The most important finding of this study is that bacteria achieve their strongest defense not by using a "single trick," but by "combining multiple tricks."

Example: When simultaneously "breaking the iron truck (closing the gate)" and "reinforcing the shield (degrading)," Cefiderocol is completely neutralized, resulting in a state of "ineffectiveness (resistance)."

🚨 Message to Us

There is no "Panacea" anymore: While Cefiderocol is an excellent drug, it is not universal. Bacteria quickly devise new tricks.
Testing is Life: It is impossible to tell by appearance which bacteria possess which tricks (which enzymes or mutations). Therefore, it is essential to detailedly investigate "which drug is effective" each time (susceptibility testing).
Beware of NDM-1: Especially when bacteria possessing the enzyme "NDM-1" are detected, careful judgment is required before using Cefiderocol.

🎯 Summary

This paper taught us that "bacteria counter the strongest drugs with a 'three-pronged' trick of closing the gate, reinforcing the shield, and shifting the target."

We must constantly monitor what tricks bacteria are using and implement countermeasures accordingly. The battle against bacteria is not merely about "administering drugs," but a "war of wisdom to decipher the enemy's strategies."

Technical Summary: Mechanisms Involved in Cefiderocol Resistance in French Pseudomonas aeruginosa Clinical Strains

Problem Statement
While cefiderocol demonstrates excellent in vitro activity against Pseudomonas aeruginosa, the emergence of resistance poses a significant clinical challenge. This study addresses the molecular mechanisms driving cefiderocol resistance (defined as MIC >2 mg/L) within a large cohort of clinical isolates, aiming to characterize the diversity and frequency of resistance determinants in the French healthcare setting.

Methodology
The researchers analyzed 103 clinical P. aeruginosa strains collected from 61 hospitals across France between 2021 and 2024. The study employed a multi-faceted approach:

Phenotypic Characterization: Minimum Inhibitory Concentrations (MICs) were determined for all strains.
Genotypic Analysis: The presence of acquired $\beta$ -lactamases was assessed.
Functional Validation: To confirm the role of specific enzymes, 11 identified $\beta$ -lactamases (including the acquired cephalosporinase PAC-1 and ESBLs VEB-1 and VEB-9) were cloned into the pUCP24 vector and expressed in a susceptible host.
Mutational Analysis: The impact of specific mutations in the PDC (Pseudomonas-derived cephalosporinase) enzyme was evaluated by introducing six mutations into a PAO1 $\Delta$ blaPDC-1 background.
Transporter/Regulator Investigation: The study screened for alterations in siderophore transporters and their regulators, with specific focus on pirR mutations.

Key Results

Resistance Prevalence: MICs ranged from 4 to >128 mg/L, with 39.8% of strains exhibiting MICs >8 mg/L. Notably, 37.8% of the isolates were classified as difficult-to-treat resistant (DTR).
Role of Acquired $\beta$ -lactamases: Acquired $\beta$ -lactamases were detected in 72.8% of the strains. This included carbapenemases (39.8%), predominantly NDM-1 (29.1%), and Extended Spectrum $\beta$ -Lactamases (ESBLs) (38.8%).
Enzymatic Contribution: Cloning experiments demonstrated that the expression of specific acquired $\beta$ -lactamases, including PAC-1, VEB-1, and VEB-9, resulted in marked increases in cefiderocol MICs, reaching up to a 128-fold elevation.
PDC Mutations: Introduction of six specific mutations (F121L, G157D, T70I, E219K, among others) into the PDC enzyme background increased MICs up to 4 mg/L. These mutations also conferred cross-resistance to ceftolozane/tazobactam.
Siderophore Transport Defects: Alterations in siderophore transporters or regulators were identified in 38.8% of the strains. The most frequent alteration was a frameshift mutation in pirR (R132fs), leading to PirR inactivation. Functional confirmation in the PAO1 strain verified that PirR inactivation contributes to cefiderocol resistance.

Significance and Conclusions
The study concludes that cefiderocol resistance in these clinical strains is a multifactorial phenomenon. The primary drivers are the acquisition of $\beta$ -lactamases (specifically ESBLs and carbapenemases) and impaired siderophore uptake mechanisms involving transporters (PiuA/PiuD) and regulators (PirA, PiuC). These combined mechanisms are responsible for high-level resistance (MIC >8 mg/L).

The authors highlight the polyclonal distribution and the diversity of resistance mechanisms observed, underscoring the necessity for routine susceptibility testing and ongoing surveillance. A critical finding is the association with NDM producers; the paper asserts that detection of NDM-producing strains is essential, as cefiderocol should be used with caution in this specific context.